Alnylam Gets $20M From Takeda

Alnylam Pharmaceuticals said today it has earned a $20 million milestone payment from Japan-based Takeda Pharmaceutical as part of the collaboration formed between the companies in May. The money is for transferring documents, materials, and know-how to Takeda for developing RNA interference-based drugs. Alnylam (NASDAQ: ALNY) has already received a $100 million upfront payment from Takeda for closing the deal.

Trending on Xconomy